The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
Open accessAbstract
Progressive multiple sclerosis is characterized by the gradual accrual of disability independent of relapses and can occur with disease onset (primary progressive) or preceded by a relapsing disease course (secondary progressive). An effective disease modifying treatment for progressive multiple sclerosis has not been identified, and the results of clinical trials to date have been generally disappointing. Ongoing advances in our understanding of pathogenesis, identification of novel targets for neuro-protection, and improved outcome measures have the potential to lead to effective treatments for progressive multiple sclerosis. In this review lessons learned from previous clinical trials and perspectives from current trials in progressive multiple sclerosis are summarized. Promising clinical, imaging, and biological markers will also be reviewed, along with novel clinical trial designs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Fischl, B. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2012.01.021 · Cited by 9,526
Axonal transection in the lesions of multiple sclerosis
Trapp, B. D., Peterson, J., Ransohoff, R. M., Rudick, R., Mörk, S., & Bö, L. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801293380502 · Cited by 4,029
Defining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationPaced Auditory Serial-Addition Task: A Measure of Recovery from Concussion
Gronwall, D. M. A. (1977) · Perceptual and Motor Skills · doi:10.2466/pms.1977.44.2.367 · Cited by 2,395
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · Trials · doi:10.1186/1745-6215-11-32 · Cited by 1,871
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Peterson, J. W., Bö, L., Mörk, S., Chang, A., & Trapp, B. D. (2001) · Annals of Neurology · doi:10.1002/ana.1123 · Cited by 1,403
Subpial Demyelination in the Cerebral Cortex of Multiple Sclerosis Patients
Bø, L., Vedeler, C. A., Nyland, H. I., Trapp, B. D., & Mørk, S. J. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.7.723 · Cited by 757
Research works printed but not linked: 152
- Mahad, 2015, Pathological mechanisms in progressive multiple sclerosis, Lancet Neurol, 14, 183, 10.1016/S1474-4422(14)70256-X · DOI · Paper page
- Miller, 2012, Treatment of relapsing-remitting multiple sclerosis: current approaches and unmet needs, Curr Opin Neurol, 25, S4, 10.1097/01.wco.0000413319.87092.19 · DOI
- Wiendl, 2009, Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes, Neurology, 72, 1008, 10.1212/01.wnl.0000344417.42972.54 · DOI
- 1988, Double-masked trial of azathioprine in multiple sclerosis, Lancet, 332, 179
- 1990, Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial, Ann Neurol, 27, 591, 10.1002/ana.410270603 · DOI · Paper page
- 1991, The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis, Lancet, 337, 441, 10.1016/0140-6736(91)93389-Q · DOI · Paper page
- Noseworthy, 1998, The Mayo Clinic-Canadian Cooperative trial of sulfasalazine in active multiple sclerosis, Neurology, 51, 1342, 10.1212/WNL.51.5.1342 · DOI
- Kappos, 1998, Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosis, Lancet, 352, 1491, 10.1016/S0140-6736(98)10039-9 · DOI · Paper page
- Noseworthy, 2000, Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators, Neurology, 54, 1726, 10.1212/WNL.54.9.1726 · DOI · Paper page
- Rice, 2000, Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI study group, Neurology, 54, 1145, 10.1212/WNL.54.5.1145 · DOI · Paper page
- 2001, Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results, Neurology, 56, 1496, 10.1212/WNL.56.11.1496 · DOI · Paper page
- Cohen, 2002, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, 59, 679, 10.1212/WNL.59.5.679 · DOI · Paper page
- Hartung, 2002, Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial, Lancet, 360, 2018, 10.1016/S0140-6736(02)12023-X · DOI · Paper page
- Andersen, 2004, Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 75, 706, 10.1136/jnnp.2003.010090 · DOI
- Hommes, 2004, Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial, Lancet, 364, 1149, 10.1016/S0140-6736(04)17101-8 · DOI · Paper page
- Pohlau, 2007, Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study, Mult Scler, 13, 1107, 10.1177/1352458507078400 · DOI
- Wolinsky, 2007, Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial, Ann Neurol, 61, 14, 10.1002/ana.21079 · DOI · Paper page
- Hawker, 2009, Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial, Ann Neurol, 66, 460, 10.1002/ana.21867 · DOI · Paper page
- Freedman, 2011, A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS, Neurology, 77, 1551, 10.1212/WNL.0b013e318233b240 · DOI
- Zajicek, 2013, Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial, Lancet Neurol, 12, 857, 10.1016/S1474-4422(13)70159-5 · DOI
- Brochet, 2013, Double-blind, randomized, controlled study of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis: PROMESS study, Multiple sclerosis (Houndmills, Basingstoke, England), 19, 51
- Khatri, 1985, Chronic progressive multiple sclerosis: Double-blind controlled study of plasmapheresis in patients taking immunosuppressive drugs, Neurology, 35, 312, 10.1212/WNL.35.3.312 · doi:10.1212/wnl.35.3.312
- Gordon, 1985, A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis, Can J Neurol Sci, 12, 39, 10.1017/S0317167100046564 · doi:10.1017/s0317167100046564
- Cook, 1986, Effect of total lymphoid irradiation in chronic progressive multiple sclerosis, Lancet, 1, 1405, 10.1016/S0140-6736(86)91554-0 · doi:10.1016/s0140-6736(86)91554-0
- Kastrukoff, 1990, Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation, Neurology, 40, 479, 10.1212/WNL.40.3_Part_1.479 · DOI
- Bornstein, 1991, A placebo-controlled, double-blind, randomized, two-center, pilot trial of cop 1 in chronic progressive multiple sclerosis, Neurology, 41, 533, 10.1212/WNL.41.4.533 · DOI · Paper page
- Sipe, 1994, Cladribine in treatment of chronic progressive multiple sclerosis, Lancet, 344, 9, 10.1016/S0140-6736(94)91046-4 · DOI · Paper page
- Wiles, 1994, Total lymphoid irradiation in multiple sclerosis, J Neurol Neurosurg Psychiatry, 57, 154, 10.1136/jnnp.57.2.154 · doi:10.1136/jnnp.57.2.154
- Milligan, 1994, A placebo-controlled trial of isoprinosine in patients with multiple sclerosis, J Neurol Neurosurg Psychiatry, 57, 164, 10.1136/jnnp.57.2.164 · DOI
- Goodkin, 1995, Low-dose (7·5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis, Ann Neurol, 37, 30, 10.1002/ana.410370108 · DOI · Paper page
- Cazzato, 1995, Double-blind, placebo-controlled, randomized, crossover trial of high-dose methylprednisolone in patients with chronic progressive form of multiple sclerosis, Eur Neurol, 35, 193, 10.1159/000117127 · doi:10.1159/000117127
- Karussis, 1996, Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation, Neurology, 47, 341, 10.1212/WNL.47.2.341 · doi:10.1212/wnl.47.2.341
- van Oosten, 1997, Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial, Neurology, 49, 351, 10.1212/WNL.49.2.351 · DOI · Paper page
- Cook, 1997, Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis, J Neurol Sci, 152, 172, 10.1016/S0022-510X(97)00189-5 · doi:10.1016/s0022-510x(97)00189-5
- Bosco, 1997, A randomized, placebo-controlled, double-blind study on the efficacy of idebenone administered to patients suffering from chronic-progressive form of multiple sclerosis and are submitted to recurrent treatment with high dose of methylprednisolone, Nuova Rivista di Neurologia, 7, 90
- Goodkin, 1998, A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis, Neurology, 51, 239, 10.1212/WNL.51.1.239 · doi:10.1212/wnl.51.1.239
- Paolillo, 1999, Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody campath 1H, Neurology, 53, 751, 10.1212/WNL.53.4.751 · DOI · Paper page
- Coles, 2006, The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy, J Neurol, 253, 98, 10.1007/s00415-005-0934-5 · DOI · Paper page
- Skurkovich, 2001, Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis, Mult Scler, 7, 277
- Leary, 2003, Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial, Neurology, 60, 44, 10.1212/WNL.60.1.44 · DOI · Paper page
- Walker, 2005, A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis, Mult Scler, 11, 149, 10.1191/1352458505ms1134oa · doi:10.1191/1352458505ms1134oa
- Warren, 2006, Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment, Eur J Neurol, 13, 887, 10.1111/j.1468-1331.2006.01533.x · DOI
- Montanari, 2009, ASPIRE (azathioprine secondary progressive interferon treated patients randomised evaluation) study: 2-year double-blind and 1-year open, randomised, multicentre, pilot study. Multiple sclerosis functional composite (MSFC) and magnetic resonance data, Mult Scler (Houndmills, Basingstoke, England), 250, 822
- Montalban, 2009, A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis, Mult Scler, 15, 1195, 10.1177/1352458509106937 · DOI
- Kapoor, 2010, Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial, Lancet Neurol, 9, 681, 10.1016/S1474-4422(10)70131-9 · DOI · Paper page
- Karpha, 2010, PAW25 a single-centre, pilot, randomised controlled trial of recombinant human erythropoietin in primary progressive multiple sclerosis, J Neurol Neurosurg Psychiatry, 81, e30, 10.1136/jnnp.2010.226340.53 · doi:10.1136/jnnp.2010.226340.53
- Barkhof, 2010, Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?, Neurology, 74, 1033, 10.1212/WNL.0b013e3181d7d651 · DOI
- Vollmer, 2011, A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis, Mult Scler, 17, 181, 10.1177/1352458510384496 · DOI
- Connick, 2012, Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study, Lancet Neurol, 11, 150, 10.1016/S1474-4422(11)70305-2 · DOI · Paper page
- Vermersch, 2012, Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study, BMC Neurol, 12, 36, 10.1186/1471-2377-12-36 · DOI
- Arun, 2013, Targeting ASIC1 in primary progressive multiple sclerosis: evidence of neuroprotection with amiloride, Brain, 136, 106, 10.1093/brain/aws325 · DOI
- Mostert, 2013, The effect of fluoxetine on progression in progressive multiple sclerosis: a double-blind, randomized, placebo-controlled trial, ISRN Neurol, 2013, 370943, 10.1155/2013/370943 · DOI
- Chataway, 2014, Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial, Lancet, 383, 2213, 10.1016/S0140-6736(13)62242-4 · DOI · Paper page
- Casetta, 2007, Azathioprine for multiple sclerosis, Cochrane Database Syst Rev, 4, 10.1002/14651858.CD003982.pub2 · DOI
- La Mantia, 2007, Cyclophosphamide for multiple sclerosis, Cochrane Database Syst Rev, 1, 10.1002/14651858.CD002819.pub2 · doi:10.1002/14651858.cd002819.pub2
- Reston, 2011, Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review, Mult Scler, 17, 204, 10.1177/1352458510383609 · DOI
- Spelman, 2013, Defining secondary progressive multiple sclerosis: is it possible to diagnose early?, Mult Scler, 19, 38
- Miller, 2008, Differential diagnosis of suspected multiple sclerosis: a consensus approach, Mult Scler, 14, 1157, 10.1177/1352458508096878 · DOI · Paper page
- Marrie, 2008, Comorbidity, socioeconomic status and multiple sclerosis, Mult Scler, 14, 1091, 10.1177/1352458508092263 · DOI · Paper page
- Manouchehrinia, 2013, Tobacco smoking and disability progression in multiple sclerosis: United kingdom cohort study, Brain, 136, 2298, 10.1093/brain/awt139 · DOI · Paper page
- Ascherio, 2014, Vitamin D as an early predictor of multiple sclerosis activity and progression, JAMA Neurol, 71, 306, 10.1001/jamaneurol.2013.5993 · DOI · Paper page
- Kappos, 2001, Final analysis of the European multicenter trial on IFNbeta-1b in secondary-progressive MS, Neurology, 57, 1969, 10.1212/WNL.57.11.1969 · DOI
- Mantia, 2013, Interferon β for secondary progressive multiple sclerosis: a systematic review, J Neurol Neurosurg Psychiatry, 84, 420, 10.1136/jnnp-2012-303291 · DOI
- van der Graaf, 2012, Adaptive trials in clinical research: scientific and ethical issues to consider, JAMA, 307, 2379, 10.1001/jama.2012.6380 · DOI
- Wason, 2014, Adaptive designs for clinical trials assessing biomarker-guided treatment strategies, Br J Cancer, 110, 1950, 10.1038/bjc.2014.156 · DOI
- Thall, 2000, Evaluating multiple treatment courses in clinical trials, Stat Med, 19, 1011, 10.1002/(SICI)1097-0258(20000430)19:8<1011::AID-SIM414>3.0.CO;2-M · doi:10.1002/(sici)1097-0258(20000430)19:8<1011::aid-sim414>3.0.co;2-m
- Muller, 2001, Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches, Biometrics, 57, 886, 10.1111/j.0006-341X.2001.00886.x · DOI · Paper page
- Friede, 2011, Designing a seamless phase II/III clinical trial using early outcomes for treatment selection: an application in multiple sclerosis, Stat Med, 30, 1528, 10.1002/sim.4202 · DOI
- Chataway, 2011, A novel adaptive design strategy increases the efficiency of clinical trials in secondary progressive multiple sclerosis, Mult Scler, 17, 81, 10.1177/1352458510382129 · DOI
- Rudick, 2014, Multiple sclerosis outcome assessments consortium: genesis and initial project plan, Mult Scler, 20, 12, 10.1177/1352458513503392 · DOI
- Barkhof, 2011, MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials, Nat Rev Neurol, 8, 13, 10.1038/nrneurol.2011.190 · DOI
- Hobart, 2000, Kurtzke scales revisited: the application of psychometric methods to clinical intuition, Brain, 123, 1027, 10.1093/brain/123.5.1027 · DOI · Paper page
- Noseworthy, 1990, Interrater variability with the expanded disability status scale (EDSS) and functional systems (FS) in a multiple sclerosis clinical trial. The Canadian Cooperation MS Study Group, Neurology, 40, 971, 10.1212/WNL.40.6.971 · DOI · Paper page
- Whitaker, 1995, Outcomes assessment in multiple sclerosis clinical trials: a critical analysis, Mult Scler, 1, 37, 10.1177/135245859500100107 · DOI · Paper page
- Hobart, 2004, Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the expanded disability status scale and multiple sclerosis functional composite, Mult Scler, 10, 41, 10.1191/1352458504ms983oa · DOI
- Verdier-Taillefer, 1991, Observer disagreement in rating neurologic impairment in multiple sclerosis: facts and consequences, Eur Neurol, 31, 117, 10.1159/000116658 · doi:10.1159/000116658
- Lamers, 2014, Assessing upper limb function in multiple sclerosis, Mult Scler, 20, 775, 10.1177/1352458514525677 · DOI
- Brissart, 2010, Integration of cognitive impairment in the expanded disability status scale of 215 patients with multiple sclerosis, Eur Neurol, 64, 345, 10.1159/000322140 · DOI
- Kragt, 2008, Responsiveness and predictive value of EDSS and MSFC in primary progressive MS, Neurology, 70, 1084, 10.1212/01.wnl.0000288179.86056.e1 · DOI
- Rudick, 1997, Recommendations from the national multiple sclerosis society clinical outcomes assessment task force, Ann Neurol, 42, 379, 10.1002/ana.410420318 · DOI · Paper page
- Cutter, 1999, Development of a multiple sclerosis functional composite as a clinical trial outcome measure, Brain, 122, 871, 10.1093/brain/122.5.871 · DOI · Paper page
- Rudick, 2002, The multiple sclerosis functional composite: a new clinical outcome measure for multiple sderosis trials, Mult Scler, 8, 359, 10.1191/1352458502ms845oa · DOI · Paper page
- Miller, 2000, Clinical significance of the multiple sclerosis functional composite: relationship to patient-reported quality of life, Arch Neurol, 57, 1319, 10.1001/archneur.57.9.1319 · DOI
- Rudick, 2009, Assessing disability progression with the multiple sclerosis functional composite, Mult Scler, 15, 984, 10.1177/1352458509106212 · DOI
- Costelloe, 2008, The longitudinal relationship between the patient-reported multiple sclerosis impact scale and the clinician-assessed multiple sclerosis functional composite, Mult Scler, 14, 255, 10.1177/1352458507081274 · doi:10.1177/1352458507081274
- Ozakbas, 2004, Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis, J Neurol Sci, 218, 3, 10.1016/j.jns.2003.09.015 · DOI
- Cohen, 2002, Benefit of interferon beta-1a on MSFC progression in secondary progressive MS, Neurology, 59, 679, 10.1212/WNL.59.5.679 · DOI · Paper page
- Kalkers, 2001, Concurrent validity of the MS functional composite using MRI as a biological disease marker, Neurology, 56, 215, 10.1212/WNL.56.2.215 · DOI
- Fisher, 2000, Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients, Mult Scler, 6, 373, 10.1177/135245850000600602 · DOI · Paper page
- Cadavid, 2011, Clinical consequences of MRI activity in treated multiple sclerosis, Mult Scler, 17, 1113, 10.1177/1352458511405375 · DOI
- Kappos, 2010, A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis, N Engl J Med, 362, 387, 10.1056/NEJMoa0909494 · DOI · Paper page
- Fox, 2007, Optimal reference population for the multiple sclerosis functional composite, Mult Scler, 13, 909, 10.1177/1352458507076950 · DOI
- Kragt, 2006, Clinical impact of 20% worsening on timed 25-foot walk and 9-hole peg test in multiple sclerosis, Mult Scler, 12, 594, 10.1177/1352458506070768 · DOI · Paper page
- Rudick, 2009, Assessing disability progression with the multiple sclerosis functional composite, Mult Scler, 15, 984, 10.1177/1352458509106212 · DOI
- Balcer, 2003, Contrast letter acuity as a visual component for the multiple sclerosis functional composite, Neurology, 61, 1367, 10.1212/01.WNL.0000094315.19931.90 · DOI · Paper page
- Ontaneda, 2012, Revisiting the multiple sclerosis functional composite: proceedings from the national multiple sclerosis society (NMSS) task force on clinical disability measures, Mult Scler, 18, 1074, 10.1177/1352458512451512 · DOI
- Brochet, 2008, Should SDMT substitute for PASAT in MSFC? A 5-year longitudinal study, Mult Scler, 14, 1242, 10.1177/1352458508094398 · DOI
- Julian, 2011, Cognitive functioning in multiple sclerosis, Neurol Clin, 29, 507, 10.1016/j.ncl.2010.12.003 · DOI
- Bever, 1995, The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study, Mult Scler, 1, 165, 10.1177/135245859500100306 · DOI
- Buschke, 1974, Evaluating storage, retention, and retrieval in disordered memory and learning, Neurology, 24, 1019, 10.1212/WNL.24.11.1019 · DOI · Paper page
- Barbizet, 1968, Clinical and psychometrical study of a patient with memory disturbances, Int J Neurol, 7, 44
- Benedict, 2008, Repeated assessment of neuropsychological deficits in multiple sclerosis using the symbol digit modalities test and the MS neuropsychological screening questionnaire, Mult Scler, 14, 940, 10.1177/1352458508090923 · DOI · Paper page
- Borkowski, 1967, Word fluency and brain damage, Neuropsychologia, 5, 135, 10.1016/0028-3932(67)90015-2 · DOI · Paper page
- Strober, 2009, Sensitivity of conventional memory tests in multiple sclerosis: comparing the rao brief repeatable neuropsychological battery and the minimal assessment of cognitive function in MS, Mult Scler, 15, 1077, 10.1177/1352458509106615 · DOI · Paper page
- Benedict, 2012, Reliability and equivalence of alternate forms for the symbol digit modalities test: implications for multiple sclerosis clinical trials, Mult Scler, 18, 1320, 10.1177/1352458511435717 · DOI
- Sonder, 2014, Comparing long-term results of PASAT and SDMT scores in relation to neuropsychological testing in multiple sclerosis, Mult Scler, 20, 481, 10.1177/1352458513501570 · DOI
- Benedict, 2012, Brief international cognitive assessment for MS (BICAMS): international standards for validation, BMC Neurol, 12, 55, 10.1186/1471-2377-12-55 · DOI · Paper page
- Johnson, 1998, Valuation of EuroQOL (EQ-5D) health states in an adult US sample, Pharmacoeconomics, 13, 421, 10.2165/00019053-199813040-00005 · DOI · Paper page
- Ware, 1992, The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection, Med Care, 30, 473, 10.1097/00005650-199206000-00002 · DOI · Paper page
- Fisk, 2005, A comparison of health utility measures for the evaluation of multiple sclerosis treatments, J Neurol Neurosurg Psychiatry, 76, 58, 10.1136/jnnp.2003.017897 · DOI · Paper page
- Hobart, 2001, The multiple sclerosis impact scale (MSIS-29): a new patient-based outcome measure, Brain, 124, 962, 10.1093/brain/124.5.962 · DOI · Paper page
- Hayton, 2012, Clinical and imaging correlates of the multiple sclerosis impact scale in secondary progressive multiple sclerosis, J Neurol, 259, 237, 10.1007/s00415-011-6151-5 · DOI
- Kuhlmann, 2002, Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time, Brain, 125, 2202, 10.1093/brain/awf235 · DOI · Paper page
- De Stefano, 2010, Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes, Neurology, 74, 1868, 10.1212/WNL.0b013e3181e24136 · DOI · Paper page
- Rudick, 2000, Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a, Mult Scler, 6, 365, 10.1177/135245850000600601 · DOI
- Altmann, 2009, Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis, Neurology, 72, 595, 10.1212/01.wnl.0000335765.55346.fc · DOI
- Bermel, 2006, The measurement and clinical relevance of brain atrophy in multiple sclerosis, Lancet Neurol, 5, 158, 10.1016/S1474-4422(06)70349-0 · DOI · Paper page
- Tedeschi, 2005, Brain atrophy and lesion load in a large population of patients with multiple sclerosis, Neurology, 65, 280, 10.1212/01.wnl.0000168837.87351.1f · DOI
- Fisher, 2008, Gray matter atrophy in multiple sclerosis: a longitudinal study, Ann Neurol, 64, 255, 10.1002/ana.21436 · DOI · Paper page
- Fisniku, 2008, Gray matter atrophy is related to long-term disability in multiple sclerosis, Ann Neurol, 64, 247, 10.1002/ana.21423 · DOI · Paper page
- Amato, 2007, Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis, Arch Neurol, 64, 1157, 10.1001/archneur.64.8.1157 · DOI · Paper page
- Shiee, 2012, Revisiting brain atrophy and its relationship to disability in multiple sclerosis, PLoS One, 7, e37049, 10.1371/journal.pone.0037049 · DOI
- Calabrese, 2007, Cortical atrophy is relevant in multiple sclerosis at clinical onset, J Neurol, 254, 1212, 10.1007/s00415-006-0503-6 · DOI · Paper page
- Dale, 1999, Cortical surface-based analysis. I. segmentation and surface reconstruction, Neuroimage, 9, 179, 10.1006/nimg.1998.0395 · DOI · Paper page
- Nakamura, 2011, CLADA: cortical longitudinal atrophy detection algorithm, Neuroimage, 54, 278, 10.1016/j.neuroimage.2010.07.052 · DOI
- Nakamura, 2013, Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis, Neuroimage Clin, 4, 10, 10.1016/j.nicl.2013.10.015 · DOI
- Harrison, 2011, Longitudinal changes in diffusion tensor-based quantitative MRI in multiple sclerosis, Neurology, 76, 179, 10.1212/WNL.0b013e318206ca61 · DOI
- Fox, 2011, Measuring myelin repair and axonal loss with diffusion tensor imaging, AJNR Am J Neuroradiol, 32, 85, 10.3174/ajnr.A2238 · DOI
- Harrison, 2013, Tract-specific quantitative MRI better correlates with disability than conventional MRI in multiple sclerosis, J Neurol, 260, 397, 10.1007/s00415-012-6638-8 · DOI
- Schmierer, 2007, Quantitative magnetization transfer imaging in postmortem multiple sclerosis brain, J Magn Reson Imaging, 26, 41, 10.1002/jmri.20984 · DOI · Paper page
- Tortorella, 2000, A magnetization transfer histogram study of normal-appearing brain tissue in MS, Neurology, 54, 186, 10.1212/WNL.54.1.186 · DOI · Paper page
- Hayton, 2009, Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis, J Neurol, 256, 427, 10.1007/s00415-009-0110-4 · DOI
- Hayton, 2012, Longitudinal changes in magnetisation transfer ratio in secondary progressive multiple sclerosis: data from a randomised placebo controlled trial of lamotrigine, J Neurol, 259, 505, 10.1007/s00415-011-6212-9 · DOI
- Geurts, 2005, Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology, AJNR Am J Neuroradiol, 26, 572
- Evangelou, 2005, Pathological study of spinal cord atrophy in multiple sclerosis suggests limited role of local lesions, Brain, 128, 29, 10.1093/brain/awh323 · DOI
- Oh, 2013, Multiparametric MRI correlates of sensorimotor function in the spinal cord in multiple sclerosis, Mult Scler, 19, 427, 10.1177/1352458512456614 · DOI
- Theaudin, 2012, Short-term evolution of spinal cord damage in multiple sclerosis: a diffusion tensor MRI study, Neuroradiology, 54, 1171, 10.1007/s00234-012-1057-1 · DOI
- Frohman, 2008, Optical coherence tomography: a window into the mechanisms of multiple sclerosis, Nat Clin Pract Neurol, 4, 664, 10.1038/ncpneuro0950 · DOI · Paper page
- Petzold, 2010, Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis, Lancet Neurol, 9, 921, 10.1016/S1474-4422(10)70168-X · DOI · Paper page
- Abalo-Lojo, 2014, Retinal nerve fiber layer thickness, brain atrophy, and disability in multiple sclerosis patients, J Neuroophthalmol, 34, 23, 10.1097/WNO.0000000000000057 · DOI
- Saidha, 2011, Visual dysfunction in multiple sclerosis correlates better with optical coherence tomography derived estimates of macular ganglion cell layer thickness than peripapillary retinal nerve fiber layer thickness, Mult Scler, 17, 1449, 10.1177/1352458511418630 · DOI · Paper page
- Narayanan, 2014, Tracking changes over time in retinal nerve fiber layer and ganglion cell-inner plexiform layer thickness in multiple sclerosis, Mult Scler, 20, 1331, 10.1177/1352458514523498 · DOI
- Ziemann, 2011, Development of biomarkers for multiple sclerosis as a neurodegenerative disorder, Prog Neurobiol, 95, 670, 10.1016/j.pneurobio.2011.04.007 · DOI
- Burman, 2014, Assessing tissue damage in multiple sclerosis: A biomarker approach, Acta Neurol Scand, 130, 81, 10.1111/ane.12239 · DOI
- Malmestrom, 2003, Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS, Neurology, 61, 1720, 10.1212/01.WNL.0000098880.19793.B6 · DOI · Paper page
- Gunnarsson, 2011, Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab, Ann Neurol, 69, 83, 10.1002/ana.22247 · DOI · Paper page
- Kuhle, 2013, Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis, Acta Neurol Scand, 128, e33, 10.1111/ane.12151 · DOI
- Semra, 2002, Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability, J Neuroimmunol, 122, 132, 10.1016/S0165-5728(01)00455-6 · DOI
- Petzold, 2002, Markers for different glial cell responses in multiple sclerosis: clinical and pathological correlations, Brain, 125, 1462, 10.1093/brain/awf165 · DOI · Paper page
- Axelsson, 2011, Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis, J Neurol, 258, 882, 10.1007/s00415-010-5863-2 · DOI · Paper page
- Denic, 2011, The relevance of animal models in multiple sclerosis research, Pathophysiology, 18, 21, 10.1016/j.pathophys.2010.04.004 · DOI · Paper page
- Parmar, 2014, More multiarm randomised trials of superiority are needed, Lancet, 384, 283, 10.1016/S0140-6736(14)61122-3 · DOI · Paper page
Cited by
Progressive multiple sclerosis: from pathogenic mechanisms to treatment
Correale, J., Gaitán, M. I., Ysrraelit, M. C., & Fiol, M. P. (2016) · Brain · doi:10.1093/brain/aww258 · Cited by 573
Progressive multiple sclerosis: from pathophysiology to therapeutic strategies
Faissner, S., Plemel, J. R., Gold, R., & Yong, V. W. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0035-2 · Cited by 459
The immunogenetics of multiple sclerosis: A comprehensive review
Hollenbach, J. A., & Oksenberg, J. R. (2015) · Journal of Autoimmunity · doi:10.1016/j.jaut.2015.06.010 · Cited by 420
Defining secondary progressive multiple sclerosis
Lorscheider, J., Buzzard, K., Jokubaitis, V., Spelman, T., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Girard, M., Duquette, P., et al. (2016) · Brain · doi:10.1093/brain/aww173 · Cited by 415
Synaptopathy connects inflammation and neurodegeneration in multiple sclerosis
Mandolesi, G., Gentile, A., Musella, A., Fresegna, D., De Vito, F., Bullitta, S., Sepman, H., Marfia, G. A., & Centonze, D. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.222 · Cited by 286
Metadata
- Authors
- Ontaneda, D., Fox, R. J., & Chataway, J.
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 14
- Issue
- 2
- Pages
- 208-223
- ISSN
- 1474-4422 (ISSN-L)
- OpenAlex
- W2072808323
- Cited by
- 220
- References
- 17
- FWCI
- 24.09
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. https://app.cochat.ai/papers/10.1016/s1474-4422(14)70264-9
- The paper
- Ontaneda, D., Fox, R. J., & Chataway, J. (2015). Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(14)70264-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.